GVHD
GVHD
Advertisement
Elaine S. DeMeyer, RN, MSN, AOCN®, BMTCN®GVHD | November 4, 2024
Oncology nurses are integral to the success of ECP, as they provide ongoing education and psychosocial support to patients.
Read More
John F. DiPersio, MD, PhDGVHD | October 29, 2024
Hear expert insights on how GVHD research is evolving as investigators evaluate new prevention and treatment strategies.
Elaine S. DeMeyer, RN, MSN, AOCN®, BMTCN®GVHD | October 25, 2024
Before axatilimab, targeting the CSF-1R pathway was not previously studied in cGVHD.
Elaine S. DeMeyer, RN, MSN, AOCN®, BMTCN®GVHD | October 24, 2024
New research and therapeutic approaches are challenging long-held beliefs about this type of graft.
Emilie Plantamura, PharmD, PhDGVHD | October 8, 2024
The ongoing trial is evaluating if MaaT033 can increase survival by preventing complications such as GVHD.
Elaine S. DeMeyer, RN, MSN, AOCN®, BMTCN®GVHD | October 1, 2024
It's critical for oncology nurses to encourage these patients to monitor their blood pressure at home.
Elaine S. DeMeyer, RN, MSN, AOCN®, BMTCN®GVHD | October 1, 2024
Renal toxicity occurs in approximately 75% of all patients who receive allogeneic stem cell transplants.
Cancer Nursing Today EditorsGVHD | September 10, 2024
A new study highlights the importance of effective management and close monitoring of GVHD.
Katie KoskoGVHD | August 30, 2024
Learn how an early intervention with oral mucosal barrier protective agents can help patients with chronic oral GVHD.
Katie KoskoGVHD | August 29, 2024
Learn what a team in Sweden found when they began offering home care after allogeneic HSCT for patients who lived nearby.
Elaine S. DeMeyer, RN, MSN, AOCN®, BMTCN®GVHD | August 23, 2024
Learn how oncology nurses can address the challenges associated with early detection, diagnosis, and management.
Elaine S. DeMeyer, RN, MSN, AOCN®, BMTCN®GVHD | August 22, 2024
It's critical for oncology nurses understand and recognize the 3 atypical lung cGVHD conditions.
Katie KoskoGVHD | August 20, 2024
A small study evaluated the ROCK2 inhibitor for treatment of ocular GVHD because corneal epithelial cells express ROCK2.
Elaine S. DeMeyer, RN, MSN, AOCN®, BMTCN®GVHD | August 6, 2024
Oncology nurses must familiarize themselves with CNS and PNS cGVHD to improve patient outcomes.
Elaine S. DeMeyer, RN, MSN, AOCN®, BMTCN®GVHD | August 5, 2024
With better understanding of CNS cGVHD, oncology nurses can help ensure early recognition and reporting.
Katie KoskoGVHD | July 26, 2024
In the United States, 33%-50% of patients receiving an allogeneic transplant develop acute GVHD.
Elaine S. DeMeyer, RN, MSN, AOCN®, BMTCN®GVHD | July 9, 2024
There are 5 types of immune-mediated cytopenias, each with provisional diagnostic criteria.
Elaine S. DeMeyer, RN, MSN, AOCN®, BMTCN®GVHD | July 9, 2024
Nurses have a critical role in managing cGVHD-related serositis, including patient assessment, direct care, and education.
Katie KoskoConferences | July 5, 2024
Researchers presented real-world data on the cGVHD treatment during the EHA 2024 Congress.
Katie KoskoGVHD | July 4, 2024
Certain predictive markers may help identify patients who "experience significant benefits" from upfront use of this therapy.
Advertisement
Advertisement
Advertisement